Corcept Therapeutics Inc. (NASDAQ:CORT) dropped 7.58% on Monday after a surge in intra-day trading due to positive news on its Phase 3 trial for ovarian cancer treatment. Despite early profits, the company reported promising results in reducing disease progression and mortality risk.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing